|
CAMBRIDGE, Mass. (AP) -- Drug developer Dyax Corp. on Wednesday said it registered with the Securities and Exchange Commission for a potential securities offering worth up to $100 million. Dyax filed a universal shelf registration statement with the SEC, which enables the company to offer and sell up to $100 million of its common stock, debt securities and other types of securities once the SEC declares it effective. The company said it does not have any commitments or immediate plans to sell securities under the registration statement. Proceeds from the potential offering would be used for general corporate purposes, including financing the company's clinical development and discovery programs.
|